araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 48-year-old male with Lung adenocarcinoma. Genetic variant: MET Amplification. Other conditions: Emphysema.

Clinical trial: Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Summary: RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.
  PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Detailed description: OBJECTIVES:
  -  Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies.
  -  Determine the efficacy of this treatment, in terms of local control, in these patients.
  -  Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients.
  OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours.
  Patients are followed at 1, 3, 6, and 12 months.
  PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Eligibility: Inclusion Criteria:
  -  Diagnosis of a primary or secondary intrathoracic malignancy
  -  Any cell type or origin
  -  Involving the intrapulmonary, mediastinal, or pleural/chest wall
  -  Inoperable primary or metastatic cancer to the lung
  -  Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
  -  Single or multiple lesions that are non-contiguous with vital structures or organs such as:
  -  Trachea
  -  Heart
  -  Aorta
  -  Great vessels
  -  Esophagus
  -  Less than 5 cm in largest dimension
  -  Accessible via percutaneous transthoracic route
  -  Hepatic:
  -  Coagulation profile normal

Relevance to patient case: not relevant
Patient case: 48-year-old male with Lung adenocarcinoma. Genetic variant: MET Amplification. Other conditions: Emphysema.

Clinical trial: Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Summary: This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.

Detailed description: This study evaluates the use of Targretin capsules (bexarotene) in combination with Carboplatin and Paclitaxel for the treatment of metastatic non-small cell lung cancer in patients who have not yet received chemotherapy for their lung cancer. Every patient receives a platinum-containing chemotherapy every three weeks for at least four chemotherapy cycles (approximately four months). Half of the patients are randomly assigned to receive Targretin capsules once daily in addition to the chemotherapy. The other half is randomized to receive a standard platinum-containing chemotherapy without Targretin capsules.

Eligibility: Patients must have:
  -  Pathologic (histologic or cytologic) confirmation of NSCLC
  -  Stage IIIB with malignant pleural effusion or Stage IV disease
  -  At least one measurable or evaluable NSCLC lesion that has not been previously irradiated unless radiation therapy was more than three weeks prior to entry in the study and the lesion has been shown to have progressed subsequent to the radiation therapy
  -  ECOG performance status 0 or 1
  -  Adequate organ system function
  -  Fasting serum triglycerides that are within the age-adjusted normal range (or normalized with appropriate intervention such as antilipid therapy prior to the initiation of Targretin capsule therapy).
  Patients must be able to complete at least four cycles of combination chemotherapy (i.e., approximately four months)
  Patients must not have had:
  -  Brain metastasis
  -  Prior chemotherapy for NSCLC
  -  Prior platinum-based chemotherapy for any indication

Relevance to patient case: not relevant
Patient case: 48-year-old male with Lung adenocarcinoma. Genetic variant: MET Amplification. Other conditions: Emphysema.

Clinical trial: Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Summary: This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.

Detailed description: This study evaluates the use of Targretin capsules (bexarotene) in combination with Cisplatin and Vinorelbine for the treatment of metastatic non-small cell lung cancer in patients who have not yet received chemotherapy for their lung cancer. Every patient receives a platinum-containing chemotherapy every four weeks for at least four chemotherapy cycles (approximately four months). Half of the patients are randomly assigned to receive Targretin capsules once daily in addition to the chemotherapy. The other half is randomized to receive a standard platinum-containing chemotherapy without Targretin capsules.

Eligibility: Patients must have:
  -  Pathologic (histologic or cytologic) confirmation of NSCLC
  -  Stage IIIB with malignant pleural effusion or Stage IV disease
  -  At least one measurable or evaluable NSCLC lesion that has not been previously irradiated unless radiation therapy was more than three weeks prior to entry in the study and the lesion has been shown to have progressed subsequent to the radiation therapy
  -  ECOG performance status 0 or 1
  -  Adequate organ system function
  -  Fasting serum triglycerides that are within the age-adjusted normal range (or normalized with appropriate intervention such as antilipid therapy prior to the initiation of Targretin capsule therapy).
  Patients must be able to complete at least four cycles of combination chemotherapy (i.e., approximately four months)
  Patients must not have had:
  -  Brain metastasis
  -  Prior chemotherapy for NSCLC
  -  Prior platinum-based chemotherapy for any indication

Relevance to patient case: not relevant
Patient case: 48-year-old male with Lung adenocarcinoma. Genetic variant: MET Amplification. Other conditions: Emphysema.

Clinical trial: US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation

Summary: The purpose of this study is to determine whether the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System is safe in patients with advanced emphysema.

Detailed description: Patients with emphysema currently have limited treatment choices. Many patients are treated with steroids and inhaled medications, which often provide little or no benefit. Recently, lung volume reduction surgery has become an accepted therapy for emphysema. Lung volume reduction surgery involves the removal of a diseased portion of the lung, which enables the remaining, healthier portions of the lung to function better. This procedure, although effective, is complicated and risky.
  Aeris Therapeutics has developed the Aeris Bronchoscopic Lung Volume Reduction System for treatment of patients with advanced emphysema. The Aeris BLVR System is designed to reduce lung volume without surgery. Patients are treated under anesthesia using a bronchoscope to direct treatment to the most damaged areas of the lung. The treatment is expected to reduce lung volume by shrinking the diseased areas of the lung. The purpose of the current study is to find out whether the Aeris BLVR System is safe in patients with advanced emphysema. The risks associated with the treatment are expected to be similar to those associated with general anesthesia and bronchoscopy.

Eligibility: Inclusion Criteria:
  -  Advanced emphysema
  -  Limited exercise capacity and persistent symptoms despite medical therapy
  -  Age between 18 and 75
  -  No significant heart, kidney or liver disease
  -  Willingness and ability to tolerate bronchoscopy
  -  No prior Lung Volume Reduction Surgery or Lung Transplantation
  -  Screening test results indicating that the procedure is appropriate

Relevance to patient case: not relevant
Patient case: 48-year-old male with Lung adenocarcinoma. Genetic variant: MET Amplification. Other conditions: Emphysema.

Clinical trial: Ispinesib In Combination With Capecitabine In Patients With Solid Tumors

Summary: The purpose of this study is to determine the dose regimen of Ispinesib in combination with capecitabine in patients with solid tumors. Ispinesib is dosed by 1-hour intravenous infusion every 3 weeks and capecitabine is dosed orally, twice a day for 14 days with a 1 week rest period. A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with Ispinesib. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.


Eligibility: Inclusion criteria:
  -  Histologically or cytologically confirmed diagnosis of an advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no standard therapy.
  -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2.
  -  Bone marrow function: - ANC greater than 1500/mm3.
  -  Platelet count greater than or equal to 100,000/mm3.
  -  Hemoglobin greater than 9 g/dL.
  -  Renal function: - Calculated creatinine clearance greater than or equal to 50 mL.min.
  -  Total bilirubin greater than 1.5 mg/dL.
  -  AST/ALT less than 2.5 X upper limit of normal.
  Exclusion criteria:
  -  Females who are pregnant or nursing.
  -  Pre-existing hemolytic anemia.
  -  Pre-existing peripheral neuropathy greater than or equal grade 2.
  -  Known deficiency in dihydropyrimidine dehydrogenase (DSD).

Relevance to patient case: not relevant
Patient case: 48-year-old male with Lung adenocarcinoma. Genetic variant: MET Amplification. Other conditions: Emphysema.

Clinical trial: SB-743921 In Patients With Solid Tumors

Summary: The purpose of this study is to find a dose of SB-743921 in adult patients with solid tumors or lymphoma who have progressed on standard therapy or who have relapsed. SB-743921 is dosed by 1-hour intravenous infusion every 3 weeks. A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of the drug in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with SB-743921. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.


Eligibility: Inclusion criteria:
  -  Histologically or cytologically confirmed diagnosis of: a) Advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no standard therapy; OR b) B-cell or T-cell lymphoma (excluding HIV-associated lymphoma) that has relapsed or is refractory after prior chemotherapy or radiotherapy and autologous or allogeneic bone marrow transplantation (if appropriate) AND/OR for which salvage chemotherapy, radiotherapy, or bone marrow transplantation is not indicated or has been refused by the patient.
  -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2.
  Exclusion criteria:
  -  Pre-existing hemolytic anemia.
  -  Pre-existing peripheral neuropathy greater than or equal grade 2.
  -  Absolute neutrophil count less than 1,500/mm3.
  -  Platelets less than 100,000/mm3.
  -  Hemoglobin less than 9 g/dL.
  -  Total bilirubin greater than1.5 mg/dL.
  -  AST/ALT greater than 2.5 X upper limit of normal.
  -  Creatinine clearance less than or equal to 60 mL/min.

Relevance to patient case: not relevant
Patient case: 48-year-old male with Lung adenocarcinoma. Genetic variant: MET Amplification. Other conditions: Emphysema.

Clinical trial: Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

Summary: The purpose of this study is to determine the dose regimen of Ispinesib in combination with carboplatin in patients with solid tumors. Ispinesib is dosed by 1-hour intravenous infusion and carboplatin is dosed by 30 minute intravenous infusion every 3 weeks (on the same day). A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with Ispinesib. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.


Eligibility: Inclusion criteria:
  -  Histologically or cytologically confirmed diagnosis of an advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no standard therapy.
  -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2.
  Exclusion criteria:
  -  Females who are pregnant or nursing.
  -  Pre-existing hemolytic anemia.
  -  Pre-existing peripheral neuropathy greater than or equal grade 2. Greater than or equal to 4 prior chemotherapy regimens including neoadjuvant/adjuvant chemotherapy, except breast cancer subjects who may have received more than 4 prior chemotherapy regimens.
  -  Absolute neutrophil count less than 1,500/mm3.
  -  Platelets less than 100,000/mm3.
  -  Hemoglobin less than 9 g/dL.
  -  Total bilirubin greater than1.5 mg/dL.
  -  AST/ALT greater than 2.5 X upper limit of normal.
  -  Creatinine clearance less than or equal to 50 mL/min (calculated by the Cockcroft Gault Formula).
  -  Known contra-indications to the use of carboplatin, cisplatin, or other platinum-containing compounds.

Relevance to patient case: not relevant
Patient case: 48-year-old male with Lung adenocarcinoma. Genetic variant: MET Amplification. Other conditions: Emphysema.

Clinical trial: Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung

Summary: The purpose of this trial is to figure out what effects (good or bad) the investigational drug agent called Tarceva (erlotinib; OSI-774) has on women with previously untreated adenocarcinoma.

Detailed description: Patients will start taking Tarceva daily by mouth on Day 1 and will continue taking this medication daily at home, until participation in the study ends.
  Every 28 days (one cycle) while the patient is taking Tarceva, they will be examined in the outpatient clinic (blood test and physical examination) and the doctor will determine if they should continue taking Tarceva.
  After every two cycles of treatment (every 8 weeks) standard radiological testing (CT scans, MRIs, and/or x-rays) of the cancer site(s) will be done to assess the response to the Tarceva treatment.
  While the patient is on this study and at the end of the study, the patient will undergo blood and urine tests, medical history evaluation, physical exams including measures of vital signs (blood pressure, heart rate, temperature, and respiration), bone scans, tumor biopsy sample, and various radiological tests to monitor the cancer and the patients health.
  The length of time on the study depends upon how the cancer responds to Tarceva and whether or not the patient experiences unacceptable side effects.

Eligibility: Inclusion Criteria:
  -  Female
  -  Diagnosis of adenocarcinoma of the lung
  -  Patient has had at least one core biopsy of her tumor
  -  Must be willing to undergo epidermal growth factor receptor (EGFR) mutation testing of her tumor
  -  Stage IV or IIIB non-small cell lung cancer
  -  Non-smoker or former smoker. Non-smoker is defined as a person who smoked 100 or less cigarettes in her lifetime while a former smoker is defined as a person who has quit smoking one or more years ago.
  -  Three or more weeks since last radiation therapy
  -  Three or more weeks since last major surgery
  -  Must at least be able to walk and capable of taking care of herself although unable to carry out work activities
  -  Life expectancy of 8 weeks or more
  -  Blood tests that show kidneys, liver and bone marrow to be working adequately
  -  Women of child-bearing potential must agree to use adequate contraception prior to study entry and for the entire time enrolled in study
  Exclusion Criteria:
  -  Prior exposure to Tarceva (OSI-774, erlotinib)
  -  Uncontrolled central nervous system problems
  -  Prior chemotherapy regimen
  -  Difficulty swallowing
  -  A disease or disorder that interferes with ability to digest and absorb food
  -  Incomplete healing of previous oncologic or other major surgery
  -  Significant medical history or unstable medical condition such as heart failure, active infection, uncontrolled high blood pressure
  -  Pregnant or breast feeding
  -  A medical condition that could make it unsafe for patient to participate in this study

Relevance to patient case: not relevant
Patient case: 48-year-old male with Lung adenocarcinoma. Genetic variant: MET Amplification. Other conditions: Emphysema.

Clinical trial: A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

Summary: This is a Phase II open-label trial evaluating the efficacy, and safety of Erbitux in patients with mucinous gastrointestinal adenocarcinoma involving the peritoneal surface.


Eligibility: Inclusion Criteria:
  -  Able to take care of self. Out of bed less than 50% of the day
  -  Absolute neutrophil count >=1,500
  -  Platelet count >=100,000
  -  Total bilirubin count <=1.5 times the upper limit of normal
  Exclusion Criteria:
  -  Prior epidermal growth factor receptor antibody
  -  Prior treatment with Erbitux
  -  Other cancers

Relevance to patient case: not relevant
Patient case: 48-year-old male with Lung adenocarcinoma. Genetic variant: MET Amplification. Other conditions: Emphysema.

Clinical trial: SB-715992 In Combination With Docetaxel In Patients With Solid Tumors

Summary: The purpose of this study is to determine the dose regimen of SB-715992 in combination with docetaxel in patients with solid tumors. SB-715992 and docetaxel were dosed by 1-hour intravenous infusion every 3 weeks (on the same day). A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with SB-715992. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.


Eligibility: Inclusion criteria:
  -  Histologically or cytologically confirmed diagnosis of an advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no standard therapy.
  -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2.
  Exclusion criteria:
  -  Females who are pregnant or nursing.
  -  Pre-existing hemolytic anemia.
  -  Pre-existing peripheral neuropathy greater than or equal grade 2. Greater than or equal to 4 prior chemotherapy regimens including neoadjuvant/adjuvant chemotherapy, except breast cancer subjects who may have received more than 4 prior chemotherapy regimens.
  -  Absolute neutrophil count less than 1,500/mm3.
  -  Platelets less than 100,000/mm3.
  -  Hemoglobin less than 9 g/dL.
  -  Total bilirubin greater than1.5 mg/dL.
  -  AST/ALT greater than 2.5 X upper limit of normal.
  -  Creatinine clearance less than or equal to 60 mL/min (calculated by the Cockcroft Gault Formula).
  -  Known contraindications to the use of docetaxel or to other drugs formulated with polysorbate 80.

Relevance to patient case: not relevant
Patient case: 48-year-old male with Lung adenocarcinoma. Genetic variant: MET Amplification. Other conditions: Emphysema.

Clinical trial: PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC)

Summary: The objective of this pharmacoeconomics (PE) study is to evaluate the cost- effectiveness analysis and cost-utility analysis of IRESSA® as first line treatment of NSCLC from the society perspective, based on resources and outcomes from patients who met the inclusion criteria for this naturalistic study comparing to existing first line platinum-based regimen chemotherapy.

Detailed description: Patients with late-stage NSCLC are often symptomatic, with specific pulmonary problems (eg, cough, breathlessness, hemoptysis) and general symptoms (eg. fatigue, weight loss) that can cause extreme distress to the patient. Therefore, improvements in disease-related symptoms and quality of life (QoL) are the key desired outcomes of medical management.7 Effective, palliative, low-toxicity with reasonable treatment cost for patients with advanced NSCLC are needed. Recently, more and more countries consider evidence of economic value along with clinical efficacy.
  The epidermal growth factor receptor (EGFR) is a promising target for anticancer therapy because it is expressed or highly expressed in a variety of tumors, including NSCLC. 8,9 Furthermore, high levels of EGFR expression have been associated with a poor prognosis in lung cancer patients in several studies. 10-12 EGFR-targeted cancer therapies are currently being developed; strategies include inhibition of the intracellular tyrosine kinase domain of the receptor by small molecules such as gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE).13 Iressa is an orally active, selective EGFR tyrosine kinase inhibitor that blocks signal transduction pathways implicated in the proliferation and survival of cancer cells.

Eligibility: Inclusion Criteria:
  -  Histologically or cytologically confirmed stage IIIB/IV NSCLC No immediate need for palliative radiotherapy and No prior chemotherapy ; age > 20 Y/O; ECOG PS: 0 - 2; ANC >2000 ; PLT >100k ; Hb > 10; total bilirubin < 2.0 mg/dL; serum creatinine < 2 mg/dl; SGPT and SGOT < 2.5 ×ULN, alkaline phosphatase < 5 ×ULN ; life expectancy >6mos
  Exclusion Criteria:
  -  If the patients have brain metastases or receive radiotherapy, the disease must be stable for more than 6 weeks after the last dose of radiotherapy;
  -  2nd malignancies;
  -  Unable to swallow tablets;
  -  Patients (M/F) with reproductive potential not implementing adequate contraceptive measurements;
  -  Pregnant or lactating patients;
  -  Participation in other clinical trials within 30 days of study entry;
  -  Major systemic disease which in the investigator's opinion might confound the clinical trial.

Relevance to patient case: not relevant